Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)- deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene

Circulation

Volumn 94, Issue 9, 1996, Pages 2177-2184

  Séguret Macé, Sandrine ^a   Latta Mahieu, Martine ^a   Castro, Graciela ^c   Luc, Gerald ^c   Fruchart, Jean Charles ^c   Rubin, Edward ^b   Denèfle, Patrice ^a   Duverger, Nicolas ^a  

^a SANOFI   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

cholesterol; fatty acids; genes; lecithin cholesterol acyltransferase; lipoproteins

Indexed keywords

PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HYPOLIPOPROTEINEMIA; IMMEDIATE EARLY GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE;

EID: 0029845121     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2177     Document Type: Article

References (41)

1. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density Hpoproteins. Biochim Biophys Acta. 1991;1084:205-220.
2. Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun. 1972;46:1493-1498.
3. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
4. Norum KR, Gjone E, Glomset JA. Familial lecithin:cholesterol acyltransferase deficiency, including fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Inc; 1989:1181-1194.
5. 156→asn). J Lipid Res. 1993;34:49-58.
6. Klein HG, Santamarina-Fojo S, Duverger N, Clerc M, Dumon MF, Albers JJ, Marcovina S, Brewer HB. Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity: implications for classification and prognosis. J Clin Invest. 1993;92:479-485.
7. Mehlum A, Staels B, Duverger N, Tailleux A, Castro G, Fievet C, Luc G, Fruchart JC, Olivecrona G, Skretting G, Auwerx J, Prydz H. Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem. 1995;230:567-575.
8. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, Talley GD, Meyn SM, Hoyt RF, Marcovina SM, Albers JJ, Hoeg JM, Brewer HB, Santamarina-Fojo S. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem. 1995;270:12269-12275.
9. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice: effect of human apolipoprotein AI and human apolipoprotein AII on plasma lipoprotein cholesterol metabolism. J Clin Invest. 1995;96:1440-1448.
10. Philip R, Brunette E, Kilinski L, Murugesh D, Mcnally MA, Ucar K, Rosenblatt J, Okarma TB, Lebkowski JS. Efficient and sustained gene expression in primary T-lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 1994;14:2411-2418.
11. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Wide-spread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 1992;90:626-630.
12. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad SCi U S A. 1991;88:434-438.
13. Chen CH, Albers JJ. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for measurement of lecithin:cholesterol acyltransferase activity. J Lipid Res. 1982;23:680-691.
14. Stokke KT, Norum KR. Determination of lecithin:cholesterol acyltransfer in human blood plasma. Scand J Clin Lab Invest. 1971;27:21-27.
15. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 1986;128:417-431.
16. Fruchart JC, Fievet C, Puchois P. Apolipoproteins. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York, NY: Academic Press; 1985;3:126-138.
17. Staels B, Auwerx J, Chan L, van Tol A, Rosseneu M, Verhoeven G. Influence of development, oestrogens and food intake on apolipoprotein A-I, A-II and E mRNA in the rat liver and intestine. J Lipid Res. 1989;30:1137-1145.
18. Chomczynski P, Sacchi N. Single step method for RNA isolation by acid guanidinium-thiocyanate-phenol-cbloroform extraction. Anal Biochem. 1987;162:156-159.
19. Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G. A cell culture system for screening human serum for ability to promote cholesterol efflux. Arterioscler Thromb. 1994;14:1056-1065.
20. Chen CH, Albers JJ. Interspecies activation of lecithin-cholesterol acyltransferase by apofipoprotein A-I isolated from the plasma of humans, horses, sheep, goats and rabbits. Biochim Biophys Acta. 1983;753:40-46.
21. Fielding CJ, Fielding PE. Regulation of human plasma lecithin: cholesterol acyltransferase activity by lipoprotein acceptor cholesteryl ester content. J Biol Chem. 1981;256:2102-2104.
22. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
23. Karpe F, Johansson J, Carlson LA. Studies on the lecithin: cholesterol acyltransferase substrate properties of HDL as determined by its subclass distribution analysed by gradient gel electrophoresis. Biochim Biophys Acta. 1990;1042:310-314.
24. Liu M, Bagdade JD, Subbaiah PV. Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. J Lipid Res. 1995;36:1813-1824.
25. Duverger N, Rader D, Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Nagano M, Nakamura H, Brewer HB. Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. Eur J Biochem. 1995;227:123-129.
26. Davidson WS, Sparks DL, Lundkatz S, Phillips MC. The molecular basis for the difference in charge between pre-beta and alpha-migrating high density lipoproteins. J Biol Chem. 1994;269:8959-8965.
27. Nishida HI, Arai H, Nishida T. Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J Biol Chem. 1993;268:16352-16360.
28. Brinton EA, Eisenberg S, Breslow JL. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 1989;84:262-269.
29. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertrigfyceridemia. J Clin Invest. 1991;87:536-544.
30. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arterioscler Thromb. 1994;14:707-720.
31. Brousseau ME, Santamarina-Fojo S, Zech LA, Berard AM, Vaisman BL, Meyn SM, Powell D, Brewer HB, Hoeg JM. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits: in vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J Clin Invest. 1996;97:1844-1851.
32. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, Clerc M, Dumon MF, Fairwell T, Zech L, Santamarina-Fojo S, Brewer HB. Markedly accelerated catabolism of apolipoprotein A-II (apoA-II) and high density lipoproteins containing apoA-II in classic lecithin-cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest. 1994;93:321-330.
33. Fielding CJ, Fielding PE, Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
34. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 1988;27:25-29.
35. Atger V, de la Llera Moya M, Bamberger M, Francone O, Cosgrove P, Tall A, Walsh A, Moatti N, Rothblat G. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein A-I. J Clin Invest. 1995;96:2613-2622.
36. Czarnecka H, Yokoyama S. Lecithin:cholesterol acyltransferase reaction on cellular lipid released by free apolipoprotein-mediated efflux. Biochemistry. 1995;34:4385-4392.
37. Davidson WS, Rodrigueza WV, Lundkatz S, Johnson WJ, Rothblat GH, Phillips MC. Effects of acceptor particle size on the efflux of cellular free cholesterol. J Biol Chem. 1995;270:17106-17113.
38. Agnani G, Marcel YL. Cholesterol efflux from fibroblasts to discoidal lipoproteins with apolipoprotein-A-I (LpA-I) increases with particle size but cholesterol transfer from LpA-I to lipoproteins decreases with size. Biochemistry. 1993;32:2643-2649.
39. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein-A-I-containing lipoproteins of pre-beta and alpha-electrophoretic mobilities. J Lipid Res. 1992;33:1807-1816.
40. Denèfle P, Duverger N, Branellec D. Genetic therapies for vascular diseases and lipid disorders. Exp Opin Investigational Drugs. 1995;4:1129-1137.
41. Yeh P, Dedieu JF, Orsini C, Vigne E, Denèfle P, Perricaudet M. Efficient dual transcomplementation of adenovirus E1 and E4 regions from 293-derived cell line expressing minimal E4 functional unit. J Virol. 1996;70:559-565.